Denmark's Novo Nordisk — whose shares climbed 24.9% over 30 days on strong Q1 2026 earnings — has licensed its Parkinson's cell therapy program to Cellular Intelligence, a US-based AI-native biotech, and shuttered its internal cell therapy division entirely.1
The decision is a clear signal from one of Europe's largest pharmaceutical companies: experimental modalities are being handed to AI specialists, not developed internally.
NVIDIA's BioNeMo platform is the infrastructure layer capturing this shift. The US chipmaker has signed partnerships with Thermo Fisher Scientific and Eli Lilly, giving it direct access to proprietary biological datasets from two of the world's largest life sciences companies.1
Independent adoption is building. Terray Therapeutics and Apheris have each released models built on BioNeMo, extending the platform's reach beyond its anchor partners.1
Competition is intensifying globally. Natera, UK-linked Basecamp Research with its EDEN platform, Boltz Lab, Owkin with OwkinZero, and Edison with Kosmos have all launched competing foundation model platforms in recent months.1 The field has shifted from infrastructure scarcity to a race for differentiation through biology, data quality, and clinical results.
For Novo Nordisk, the restructuring lets it concentrate resources on its dominant GLP-1 franchise — the drug class behind blockbuster obesity and diabetes treatments that has reshaped global pharma valuations. Cellular Intelligence inherits a Parkinson's program with commercial upside.
The broader pattern holds across North America, Europe, and Asia: large pharma is repricing AI drug discovery from speculative bet to embedded R&D strategy. The question now is which platforms control the stack when the first AI-native regulatory approvals arrive.
